Vimarsana
Biggest News Aggregation in the World

Page 2 - Integra Lifescience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Integra Lifescience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Integra Lifescience Today - Breaking & Trending Today

Financial Contrast: Integra LifeSciences (NASDAQ:IART) versus Artivion (NYSE:AORT) - Vimarsana News

Financial Contrast: Integra LifeSciences (NASDAQ:IART) versus Artivion (NYSE:AORT)

Artivion (NYSE:AORT – Get Free Report) and Integra LifeSciences (NASDAQ:IART – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Risk and Volatility Artivion has a beta of 1.39, […]

Integra Lifesciences hit with FDA warning letter over Boston facility - Vimarsana News

Integra Lifesciences hit with FDA warning letter over Boston facility

The FDA says Integra Lifesciences has inadequately responded to violations that it found at the company's TEI Biosciences plant in Boston. 

Integra LifeSciences Reports Second Quarter 2023 Financial Results - Vimarsana News

Integra LifeSciences Reports Second Quarter 2023 Financial Results

PRINCETON, N.J., July 26, 2023 -- Integra LifeSciences Holdings Corporation , a leading global medical technology company, today reported financial results for the second quarter ending June 30,...

Orthopedic Soft Tissue Repair Global Market Report 2023 - Vimarsana News

Orthopedic Soft Tissue Repair Global Market Report 2023

Major players in the orthopedic soft tissue repair market are Arthrex Inc., DePuy Synthes Inc., Stryker Corporation, Wright Medical Group N.V., Zimmer...

Integra LifeSciences (NASDAQ:IART) Issues FY 2023 Earnings Guidance - Vimarsana News

Integra LifeSciences (NASDAQ:IART) Issues FY 2023 Earnings Guidance

Thomson Reuters consensus EPS estimate of $3.47. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.15 billion. The company updated its FY2023 earnings and revenue guidance.